The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, an update on global studies of the BCR-ABL/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor. Coverage brought to you by

Dajun Yang shares the history of Ascentage, talks about what makes the BCR-ABL program, which Takeda took an option on, a...